Ghassan Abou-Alfa, MD, MBA of Memorial Sloan Kettering gives his view on checkpoint inhibitors and their incorporation into treatment for unresectable HCC at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
How Will Checkpoint Inhibitors Be Incorporated Into Unresectable HCC Treatment
